US Patent

US12472224 — Ready-to-use bivalirudin compositions

Method of Use · Assigned to Maia Pharmaceuticals Inc · Expires 2039-05-20 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects ready-to-use liquid bivalirudin compositions and methods for using and preparing them.

USPTO Abstract

Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.

Drugs covered by this patent

Angiomax (BIVALIRUDIN) · Novartis

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3817`	—	Angiomax

Patent Metadata

Patent number: US12472224
Jurisdiction: US
Classification: Method of Use
Expires: 2039-05-20
Drug substance claim: No
Drug product claim: Yes
Assignee: Maia Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.